Abstract
Different authors described that transthyretin (TTR) is decreased in the cerebrospinal fluid (CSF) of Alzheimer’s disease (AD) patients and thus TTR is a potential CSF biomarker in AD. However, descriptions of what happens to TTR in plasma of these patients are lacking in the literature. We investigated TTR levels in plasma samples from 55 patients with mild-cognitive impairment (MCI), 56 patients with AD and 41 non-demented controls, and found that TTR is decreased in both MCI and AD groups, suggesting that TTR might be used for staging early AD. In MCI and AD groups, women showed significantly lower plasma TTR levels when compared to MCI and AD men, respectively, and to women control group. In the AD women group, TTR levels correlated with disease stage, reflecting disease severity. Although MCI and AD men groups presented TTR levels lower than men in the control group, the difference was not statistically significant. Genetic analysis for ApoE revealed no relationship between TTR levels and the presence of the ε4 allele, for both men and women, in both patient groups. Importantly, we assessed thyroxine binding to TTR in plasma and found, in both MCI and AD groups, that TTR had reduced capacity to carry the hormone. Finally, we measured plasma estradiol levels in women and showed a reduction in both groups. Thus, this study prompts TTR as an early plasma biomarker in AD indicating that disease modulation by TTR is gender dependent; this study provides hypotheses into the mechanisms involved.
Keywords: Alzheimer’s disease, ApoE, biomarker, disease severity, estradiol, plasma, transthyretin, thyroxine
Current Alzheimer Research
Title:Transthyretin Decrease in Plasma of MCI and AD Patients: Investigation of Mechanisms for Disease Modulation
Volume: 9 Issue: 8
Author(s): Carlos A. Ribeiro, Isabel Santana, Catarina Oliveira, Ines Baldeiras, Jorge Moreira, Maria Joao Saraiva and Isabel Cardoso
Affiliation:
Keywords: Alzheimer’s disease, ApoE, biomarker, disease severity, estradiol, plasma, transthyretin, thyroxine
Abstract: Different authors described that transthyretin (TTR) is decreased in the cerebrospinal fluid (CSF) of Alzheimer’s disease (AD) patients and thus TTR is a potential CSF biomarker in AD. However, descriptions of what happens to TTR in plasma of these patients are lacking in the literature. We investigated TTR levels in plasma samples from 55 patients with mild-cognitive impairment (MCI), 56 patients with AD and 41 non-demented controls, and found that TTR is decreased in both MCI and AD groups, suggesting that TTR might be used for staging early AD. In MCI and AD groups, women showed significantly lower plasma TTR levels when compared to MCI and AD men, respectively, and to women control group. In the AD women group, TTR levels correlated with disease stage, reflecting disease severity. Although MCI and AD men groups presented TTR levels lower than men in the control group, the difference was not statistically significant. Genetic analysis for ApoE revealed no relationship between TTR levels and the presence of the ε4 allele, for both men and women, in both patient groups. Importantly, we assessed thyroxine binding to TTR in plasma and found, in both MCI and AD groups, that TTR had reduced capacity to carry the hormone. Finally, we measured plasma estradiol levels in women and showed a reduction in both groups. Thus, this study prompts TTR as an early plasma biomarker in AD indicating that disease modulation by TTR is gender dependent; this study provides hypotheses into the mechanisms involved.
Export Options
About this article
Cite this article as:
A. Ribeiro Carlos, Santana Isabel, Oliveira Catarina, Baldeiras Ines, Moreira Jorge, Joao Saraiva Maria and Cardoso Isabel, Transthyretin Decrease in Plasma of MCI and AD Patients: Investigation of Mechanisms for Disease Modulation, Current Alzheimer Research 2012; 9 (8) . https://dx.doi.org/10.2174/156720512803251057
DOI https://dx.doi.org/10.2174/156720512803251057 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gut Permeability and Microbiota in Parkinson’s Disease: Role of Depression, Tryptophan Catabolites, Oxidative and Nitrosative Stress and Melatonergic Pathways
Current Pharmaceutical Design Mass Spectrometric Identification of Collagen Alpha-1 (III) Chain and Chondroitin Sulfate Proteoglycan-4 Nitration in Patients with Acute Pulmonary Embolism
Current Proteomics Merging Transport Data for Choroid Plexus with Blood-Brain Barrier to Model CNS Homeostasis and Disease More Effectively
CNS & Neurological Disorders - Drug Targets Medical Treatment for Neurocysticercosis: Drugs, Indications and Perspectives
Current Topics in Medicinal Chemistry Influence of Lithium Treatment on GDNF Serum and CSF Concentrations in Patients with Early Alzheimers Disease
Current Alzheimer Research Nanotechnology and Brain Tumors Drug Delivery
Recent Patents on Nanomedicine Single Amino Acid Repeats Connect Viruses to Neurodegeneration
Current Drug Discovery Technologies Electroconvulsive Therapy in Child and Adolescent Psychiatry
Current Psychiatry Reviews Early Timing of Endovascular Treatment for Aneurysmal Subarachnoid Hemorrhage Achieves Improved Outcomes
Current Neurovascular Research Treatment of Central Nervous System Tuberculosis Infections and Neurological Complications of Tuberculosis Treatment
Current Pharmaceutical Design Novel Agents in CNS Myeloma Treatment
Central Nervous System Agents in Medicinal Chemistry Diagnostic Accuracy of Sagittal TSE-T2W, Variable Flip Angle 3D TSET2W and High-resolution 3D Heavily T2W Sequences for the Stenosis of Two Localizations: The Cerebral Aqueduct and the Superior Medullary Velum
Current Medical Imaging Stem Cell Therapies for Intracerebral Hemorrhages
Current Drug Delivery Conventional (Continuous) EEG Monitoring in the NICU
Current Pediatric Reviews Insights into the Structure, Function, and Regulation of Human Cytochrome P450 1A2
Current Drug Metabolism FDG PET/MR Imaging in Major Neurocognitive Disorders
Current Alzheimer Research Natural Rubber Latex Allergy in Pediatric Patients
Current Pediatric Reviews Ribosome Inactivating Proteins (RIPs) from Momordica charantia for Anti Viral Therapy
Current Molecular Medicine Is Helicobacter pylori the Infectious Trigger for Headache?: A Review
Infectious Disorders - Drug Targets Muscular Dystrophies: Histology, Immunohistochemistry, Molecular Genetics and Management
Current Pharmaceutical Design